Nicotinamide Riboside

Nicotinamide riboside sits at the intersection of legitimate biochemistry and speculative longevity marketing. The science is real: NAD+ (nicotinamide adenine dinucleotide) is an obligate coenzyme for hundreds of metabolic reactions, and its levels decline approximately 50% between age 20 and age 60. This decline impairs mitochondrial function, sirtuin activity, and DNA repair capacity. Restoring NAD+ through precursor supplementation is a rational strategy. The question is whether NR delivers meaningful clinical benefits beyond biomarker changes.

The bioavailability data is solid. Trammell and colleagues (2016, Nature Communications, PMID 27819064) demonstrated that NR is uniquely and orally bioavailable in humans, producing dose-dependent increases in NAD+ metabolites in plasma and urine. Unlike niacin (which causes flushing) or nicotinamide (which may inhibit sirtuins at high doses), NR raises NAD+ without significant side effects. This pharmacokinetic profile established NR as the preferred NAD+ precursor for human supplementation.

The clinical trial evidence is more measured than marketing suggests. Martens and colleagues (2018, Nature Communications, PMID 29520042) conducted a randomized trial in 60 healthy middle-aged and older adults, testing 500 mg NR daily for six weeks. NAD+ levels in whole blood increased by approximately 60%, and systolic blood pressure showed a modest but significant reduction in individuals with elevated baseline BP. However, no improvements were seen in body composition, glucose homeostasis, or inflammatory markers. The trial was well-powered for biomarker endpoints but too short and small for clinical outcome assessment. A more recent study in obese adults (2024, Aging Cell, PMID 38735721) found no improvement in insulin sensitivity or mitochondrial function after 12 weeks of NR supplementation compared to placebo.

The Sinclair longevity narrative deserves critical examination. Harvard researcher David Sinclair’s popularization of NAD+ biology has driven enormous consumer interest, but his claims about NR and NMN reversing aging in humans outrun the available trial data. Mouse studies are genuinely impressive—NR extends lifespan in some models, improves muscle function, and protects against metabolic disease. Human translation remains uncertain. The honest framing: NR reliably elevates NAD+, may modestly improve blood pressure in hypertensive individuals, and has an excellent safety profile. Claims of lifespan extension, dramatic cognitive enhancement, or disease reversal in humans are premature and not supported by current RCT evidence.